Evidence map›Paper›PMID 28770321›Full record

ReviewDiabetologia2017

Metformin: clinical use in type 2 diabetes.

Elizabeth Sanchez-Rangel, Silvio E Inzucchi

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05607316 (Metformin as a Novel Treatment for Vitiligo by Targeting CD8+ T Cell Metabolism), which is not on this map. Cited by 314 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
314citing papers in PubMed, 10 pooled it
19.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05607316 phase2withdrawnnot on this mapstarted 2025, after this paper: background citation

Metformin as a Novel Treatment for Vitiligo by Targeting CD8+ T Cell Metabolism

TypeinterventionalSponsorUniversity of Massachusetts, WorcesterRan2025 to 2028Enrolled0ConditionsVitiligoArmsMetformin Hydrochloride
3 · Its place in the literature

Who cites it

314 citing papers in PubMed, 10 syntheses or guidelines pooled it, 578 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Metformin versus insulin in gestational diabetes mellitus: a systematic review.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2024
    Pooled it
  6. Pooled it
  7. Influence of Solute Carrier Family 22 Member 1 (Current diabetes reviews · 2024
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

254 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Elizabeth Sanchez-RangelSection of Endocrinology, Yale School of Medicine and Yale-New Haven Hospital, Fitkin 106, 333 Cedar Street, New Haven, CT, 06520-8020, USA.
Silvio E InzucchiSection of Endocrinology, Yale School of Medicine and Yale-New Haven Hospital, Fitkin 106, 333 Cedar Street, New Haven, CT, 06520-8020, USA. silvio.inzucchi@yale.edu.
Yale New Haven Hospital · US

Funding

DIABETES MELLITUS &DISORDERS OF METABOLISMT32DK007058 · NIDDK · YALE UNIVERSITY · PI SONIA CAPRIO, Kevan C Herold · 1986 to 2026
$9.6M
NIDDK NIH HHS T32 DK007058
6 · The paper itself

Abstract

Metformin is one of the most popular oral glucose-lowering medications, widely considered to be the optimal initial therapy for patients with type 2 diabetes mellitus. Interestingly, there still remains controversy regarding the drug's precise mechanism of action, which is thought to involve a reduction in hepatic glucose production. It is now recommended as first-line treatment in various guidelines, including that of the EASD and ADA. Its favoured status lies in its efficacy, low cost, weight neutrality and good safety profile. Other benefits have also been described, including improvements in certain lipids, inflammatory markers, and a reduction in cardiovascular events, apparently independent from the drug's glucose-lowering effect. Data have emerged questioning the previous reluctance to use this agent in those with mild to moderate chronic kidney disease. Regulations guiding its use in patients with stable, modest renal dysfunction have, as a result, become more lenient in recent years. With no long-term studies comparing it against newer glucose-lowering drugs, some of which have more robust evidence for cardioprotection, metformin's established role as 'foundation therapy' in type 2 diabetes may justifiably be challenged.

Indexed as

AnimalsBiguanidesDiabetes Mellitus, Type 2HumansHypoglycemic AgentsMetforminBiguanidesHypoglycemic AgentsMetforminBiguanidesGlucose-lowering therapyMetforminReviewType 2 diabetes mellitus

Identifiers

PMID28770321
OpenAlexW2740986674

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.